Saltar al contenido
Merck
Todas las fotos(1)

Documentos

Y0001256

Levetiracetam impurity C

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

2-Hydroxypyridine, 2(1H)-Pyridone, 2-Pyridinol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C5H5NO
Número de CAS:
142-08-5
Peso molecular:
95.10
Beilstein/REAXYS Number:
105757
MDL number:
MFCD00006268
UNSPSC Code:
41116107
PubChem Substance ID:
329831326
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

EDQM

bp

280-281 °C (lit.)

mp

105-107 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Oc1ccccn1

InChI

1S/C5H5NO/c7-5-3-1-2-4-6-5/h1-4H,(H,6,7)

InChI key

UBQKCCHYAOITMY-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam impurity C EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Referencia del producto
Descripción
Precios

1359404

Levetiracetam, United States Pharmacopeia (USP) Reference Standard

1359437

(S)-(+)-2-Aminobutanmide hydrochloride, United States Pharmacopeia (USP) Reference Standard

1359415

Levetiracetam Racemic Mixture, United States Pharmacopeia (USP) Reference Standard

1359426

Levetiracetam Related Compound A, United States Pharmacopeia (USP) Reference Standard

Y0001253

Levetiracetam, European Pharmacopoeia (EP) Reference Standard

Y0001254

Levetiracetam impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001257

Levetiracetam impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000659

Pyrrolidone, European Pharmacopoeia (EP) Reference Standard

PHR1447

Levetiracetam, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001962

(R)-(+)-α-Methylbenzylamine, European Pharmacopoeia (EP) Reference Standard

Y0001948

(S)-(+)-2-Aminobutanmide hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR2432

(S)-(+)-2-Aminobutanmide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2428

Levetiracetam Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2417

Levetiracetam Racemic Mixture, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificados de análisis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 2

1 of 2

Levetiracetam United States Pharmacopeia (USP) Reference Standard

USP

1359404

Levetiracetam

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Ken-ichi Kusakabe et al.
Bioorganic & medicinal chemistry, 21(7), 2045-2055 (2013-02-12)
Selective CB2 agonists have the potential for treating pain without central CB1-mediated adverse effects. Screening efforts identified 1,2-dihydro-3-isoquinolone 1; however, this compound has the drawbacks of being difficult to synthesize with two asymmetric carbons on an isoquinolone scaffold and of
Amanda L Steber et al.
Faraday discussions, 150, 227-242 (2011-01-01)
Studies of the gas phase structures of biomolecules provide an important connection to theoretical methods for modeling large molecular structures. The key features of biomolecule structures, such as their conformational flexibility and the complexes they form through intermolecular interactions, pose
Mingwen Zhu et al.
Chemical communications (Cambridge, England), 47(48), 12876-12878 (2011-11-15)
A highly efficient and convenient CuCl/2-pyridonate catalytic system for oxidative homocoupling of azoles affording a biazole product has been developed. With this system, a variety of biazoles have been effectively synthesized in good to excellent yields in the presence of
Istvan Horvath et al.
Archives of biochemistry and biophysics, 532(2), 84-90 (2013-02-13)
In a recent study we discovered that a ring-fused 2-pyridone compound triggered fibrillization of a key protein in Parkinson's disease, α-synuclein. To reveal how variations in compound structure affect protein aggregation, we now prepared a number of strategic analogs and
Christian Wiegand et al.
Chemical communications (Cambridge, England), 48(82), 10195-10197 (2012-09-11)
3-Substituted 2-pyridones were enantioselectively (68-90% ee) converted into the respective 3-hydroxypyridine-2,6-diones by a sequence consisting of a template-mediated type II photooxygenation and an acid-catalysed rearrangement.
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico